DGAP-News: PAION AG

JÜRGEN BECK, MD APPOINTED AS CHIEF DEVELOPMENT OFFICER AT PAION AG

- New CDO brings wealth of experience in international product developments

Aachen (Germany), 06 December 2017 - PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), today announces that Dr. Jürgen Beck has been appointed by the Supervisory Board as a new member of the Management Board of PAION AG and will be Chief Development Officer with effect from 1 January 2018. Dr. Beck has been working for PAION as a consultant since beginning of 2017. Within the Management Board, he will be responsible for product development in the future, in particular for the remimazolam development program in procedural sedation in the U.S. and for the EU Phase III program in general anesthesia.

Dr. Beck has over 25 years of experience in the European pharma business, with positions held in various drug development projects. As a graduated physician and having a diploma in business administration, he held inter alia various senior management positions at Synthélabo for many years, was longtime Managing Director of the contract research organization Monitoring Force GmbH, Senior Vice President of Medical Affairs at Epigenomics and Vice President of Clinical Operations Europe at InterMune International AG.

Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board of PAION AG, commented: "With many years of international expertise in product development, Dr. Beck is an excellent addition to the Management Board of PAION AG. Dr. Beck will move PAION further forward on its successful path and will accompany key steps towards U.S. approval and further development of remimazolam in Europe."

"On behalf of the management, I welcome Dr. Jürgen Beck as new CDO. Together, we share the vision of moving PAION to an acknowledged "PAIONeer" in sedation and anesthesia for which Dr. Beck has already inspired new momentum", Dr. Wolfgang Söhngen, CEO of PAION AG, commented.

A photo and the CV of Dr. Jürgen Beck can be found at http://www.paion.com/company/about-paion/management/.

###

About PAION
PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in the final stage of clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its development program in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anesthesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam.

PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom).

PAION's vision is to become an acknowledged "PAIONeer" in sedation and anesthesia.

Contact
Ralf Penner
Vice President Relations/Public Relations
Martinstrasse 10-12
52062 Aachen - Germany
Phone +49 241 4453-152
E-mail r.penner@paion.com
www.paion.com